CClinicalTrials.gg
CompletedNCT05623553Updated Nov 21, 2022

Evaluation of a Smartphone Based Diagnostic Tool to Assess Neonatal Jaundice in a Mexican Population

An interventional study of Picterus Jaundice Pro in Jaundice, Neonatal, sponsored by Picterus AS. Completed at 1 site in Mexico. Open to participants aged 0 Days to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-21.

Sponsored by Picterus AS · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled Jul 2018, registered Nov 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Not applicable
Ages
0 Days to 14 Days
Sex
All
01

Study summary

This corss-sectional study aims to test the performance and accuracy of the Picterus JP screening device in newborns with different skin types.

Read the detailed description

A descriptive cross-sectional study among 174 newborns was carried out at Hospital Materno-Infantil de Irapuato in Mexico during July and August 2018.

The Picterus Calibration Card will be placed on the chest of the newborn with the hole in the card placed over the infant's sternum. A validated smartphone with Picterus JP will be used to collect digital images..

02

Conditions studied

  • Jaundice, Neonatal
03

In context

Jaundice, Neonatal

105 studies on the registry are indexed under Jaundice, Neonatal; 27 are open to participants now.

This study's enrollment of 174 is above the median of 134 across 74 interventional studies indexed under Jaundice, Neonatal.

Browse Jaundice, Neonatal studies →

Lead sponsor

Picterus AS is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 14 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy newborns with or without signs of jaundice
  • Gestational age >35 weeks
  • Age 0-14 days
  • Birth weight > 1500 g.
  • Parents acceptance of their children to participate in the study.
  • Newborn needing a blood test

Exclusion criteria

Exclusion Criteria:

  • Newborns showing signs or with diagnosis of inborn diseases
  • Newborn transferred to pediatric ward for any treatment
  • Newborns who had received phototherapy.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
174 participants (actual)

Study arms

  • Experimental
    Enable high qualitative estimation of bilirubin levels in the blood of new-borns

    There is only one arm in this study which is to enable high qualitative estimation of bilirubin levels in the blood of new-borns, independent of skin color, using Picterus JP.

    Device: Picterus Jaundice Pro

Interventions

  • DevicePicterus Jaundice Pro

    Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.

    Also known as: Picterus JP

06

What researchers measure

Primary outcomes

  1. Enable high qualitative estimation of bilirubin levels in the blood of newborns using Picterus JP

    Evaluate of smartphone-based diagnostic tool (Picterus JP) for neonatal jaundice in newborns.

    Time frame: 6 months

Secondary outcomes

  1. Correlation with TsB

    Demonstrate the correlation among the estimated levels of bilirubin obtained through a smartphone based diagnostic tool with bilirubin serum levels in a population of Mexican neonates.

    Time frame: 1-2 hours

  2. Correlation with TcB

    Demonstrate the correlation among the estimated levels of bilirubin obtained through a smartphone based diagnostic tool with those obtained using a transcutaneous bilirubinometer in a population of Mexican neonates.

    Time frame: 5-10 minutes

  3. Correlation with visual assessment

    Demonstrate the correlation among the estimated levels of bilirubin obtained through a smartphone based diagnostic tool with those obtained using visual Kramer scale in a population of Mexican neonates.

    Time frame: 5-10 minutes

07

Study locations

1 site
  • Hospital Materno- Infantil de Irapuato
    Irapuato, Guanajuato 36546, Mexico
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05623553
Lead sponsor
Picterus AS
Collaborators
Norwegian University of Science and Technology Faculty of Medicine and Health Sciences Department of Public Health and Nursing, Hospital Materno- Infantil de Irapuato
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Jul 1, 2018
Primary completion
Jul 11, 2018
Completion
Aug 8, 2018
Last update
Nov 21, 2022

Study contacts

Elisabeth Darj, Prof, MD, PhD
principal investigator · NTNU Faculty of Medicine and Health Sciences, Department of Public Health and Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion